Weekly Top News – Breast Cancer – September 2, 2019

September 2, 2019

Tecentriq (atezolizumab) / Roche
Tecentriq clinical trial estimate: Data from P3 IMpassion030 trial (NCT03498716) for TNBC in 2022 (Credit Suisse) – Aug 29, 2019 – A subscription to Thomson ONE is required to gain full access to report 67838763; Page no: 11; REPORT TITLE: “Adjuvant immuno-oncology 2.0: Revisiting potential winners in new $30bn+ market”; AUTHOR: Pharma Team, European, et al; DATE: 08/19/2019

 

Keytruda (pembrolizumab) / Merck (MSD)
Keytruda clinical trial estimate: Data from P3 KEYNOTE-355 trial (NCT02819518) for 1L TNBC in December 2019 (Credit Suisse) – Aug 31, 2019 – A subscription to Thomson ONE is required to gain full access to report 67838763; Page no: 11; REPORT TITLE: “Adjuvant immuno-oncology 2.0: Revisiting potential winners in new $30bn+ market”; AUTHOR: Pharma Team, European, et al; DATE: 08/19/2019

 

Abraxane (albumin-bound paclitaxel) / Celgene, Otsuka; Tecentriq (atezolizumab) / Roche
European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer (Roche Press Release) – Aug 29, 2019 – “Roche…announced that the European Commission has approved Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression (≥1%) and who have not received prior chemotherapy for metastatic disease….Approval based on the Phase III IMpassion130 study, which showed that the combination improved outcomes in people with PD-L1-positive metastatic triple-negative breast cancer.”

 

Kadcyla (ado-trastuzumab emtansine) / Roche
Chugai files for additional indication for anti-HER2 antibody drug conjugate Kadcyla for adjuvant therapy of HER2-positive early breast cancer (Chugai Press Release) – Aug 30, 2019 – “Chugai Pharmaceutical Co., Ltd…announced…that it has filed an application to the Ministry of Health, Labour and Welfare (MHLW) in Japan for an additional indication for anti-HER2 antibody-tubulin polymerization inhibitor conjugate Kadcyla® (generic name: trastuzumab emtansine), as adjuvant therapy in patients with HER2-positive early breast cancer….This application is based on results from an open-label, randomized, global phase III clinical study (the KATHERINE study), evaluating efficacy and safety of Kadcyla adjuvant therapy compared to Herceptin in almost 1,500 people with HER2-positive early breast cancer who had invasive residual disease in the breast and/or axillary lymph nodes following neoadjuvant therapy including Herceptin.”

 

Bavencio (avelumab) / EMD Serono, Pfizer
Bavencio clinical trial estimate: Data from P3 A-Brave trial (NCT02926196) for TNBC in mid-2021 – Aug 28, 2019 – A subscription to Thomson ONE is required to gain full access to report 67838763; Page no: 13; REPORT TITLE: “Adjuvant Immuno-oncology 2.0: Revisiting potential winners in new $30bn+ market”; AUTHOR: Pharma team, European, et al; DATE: 08/19/2019

 

Tecentriq (atezolizumab) / Roche
Roche launches VENTANA PD-L1 (SP142) assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq (Roche Press Release) – Aug 29, 2019 – “Roche…announced the expanded use of the VENTANA PD-L1 (SP142) Assay in triple-negative breast cancer (TNBC) for patients living in CE (Conformité Européene) markets where the Roche cancer immunotherapy medicine Tecentriq® is approved. It is the first companion diagnostic to aid in identifying triple-negative breast cancer patients eligible for treatment with Tecentriq (atezolizumab)5 plus chemotherapy (nab-paclitaxel).”

 

Talzenna (talazoparib) / Pfizer
Pfizer wastes no time to launch Talzenna in Argentina (GBI Health) – Aug 28, 2019 – “Pharmaceutical major Pfizer this week launched its anti-breast cancer PARP inhibitor Talzenna (talazoparib) to the Argentina market, less than a month after its approval was published by the National Administration of Drugs, Foods and Medical Devices (ANMAT), as GBI reported. The drug was shown in the Phase III EMBRACA clinical trial to stop disease progression in 63% of patients with BRCA-mutated (gBRCAm) breast cancer versus only 27% in the chemotherapy control group, while increasing progression-free survival (PFS) to 8.6 months compared to 5.6 months in the control arm.”

No Comments

Post a Comment

Comment
Name
Email
Website